AstraZeneca Sells 100,000 Coronavirus Antibody Treatments to the USA

The UK's AstraZeneca announced on October 9, 2020, it received financial support of around $486 million from the US Government for the development and supply of AZD7442, the company's experimental long-acting antibody combination, under an agreement with the Biomedical Advanced Research and Development Authority (BARDA).

Additionally, AstraZeneca stated it plans to supply the US government up to 100,000 doses starting towards the end of 2020 and intends to offer up to an additional 1-million doses in 2021, under a separate agreement with BARDA.